drugset / Trial / NCT05399732

Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia

NCT05399732

Phase 2 Completed 58 enrolled Bing Han Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Aplastic anemia (AA) is a rare bone marrow failure disease characterized by bone marrow hypocellularity and peripheral blood pancytopenia. AA is divided into severe AA (SAA) and non-severe AA (NSAA) based on the degree of cytopenia. The first line therapy for SAA or transfusion dependent NSAA is either immunosuppression therapy (IST) or hematopoietic stem cell transplantation (HSCT). Little attention has been paid to patients with anemia but not transfusion dependent, whose quality of life is significantly impaired due to the anemia and other complications.

Timeline

Start
2022-12-19
Primary completion
2025-02-01
Completion
2025-04-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 3 mg/kg
Subject Cyclosporine Peptide 5 mg/kg
Subject Luspatercept Protein / enzyme biologic 1 mg/kg Subcutaneous

Indications